1h Free Analyst Time
The PD-1 and PD-L1 inhibitors market is poised to grow by $49.34 bn during 2022-2026, accelerating at a CAGR of 19.31% during the forecast period. The report on the PD-1 and PD-L1 inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of cancer, the presence of patient assistance programs, and the high target affinity and specificity of pd1 and pdl1 inhibitors.
The PD-1 and PD-L1 inhibitors market analysis includes application segment and geographic landscape.
The PD-1 and PD-L1 inhibitors market is segmented as below:
By Application
- Solid tumors
- Blood-related tumors
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the PD-1 and PD-L1 inhibitors market covers the following areas:
- PD-1 and PD-L1 inhibitors market sizing
- PD-1 and PD-L1 inhibitors market forecast
- PD-1 and PD-L1 inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global PD-1 and PD-L1 inhibitors market: Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is a strong pipeline.`
According to the report, one of the major drivers for this market is the increasing prevalence of cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akeso Inc.
- Alphamab Oncology
- Amgen Inc.
- AstraZeneca Plc
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Innovent Biologics Inc.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Merck and Co. Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Shanghai Jhunsi Biosciences Ltd.
